✦ LIBER ✦

410 Vandetanib, docetaxel and carboplatin followed by maintenance vandetanib or placebo in patients with stage IIIB, IV or recurrent non-small cell lung cancer (NSCLC): a randomized phase II study (PrE0502) by PrECOG, LLC (NCT006872970)

✍ Scribed by J. Aisner; J. Manola; S. Dakhil; P. Stella; J. Schiller

Book ID: 119603093
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 46 KB
Volume: 8
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(10)72117-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PointBreak: A Randomized Phase III Study

PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer

✍ Patel, J. D.; Socinski, M. A.; Garon, E. B.; Reynolds, C. H.; Spigel, D. R.; Ols 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 243 KB

Treatment Rationale and Study Design for

Treatment Rationale and Study Design for the PointBreak Study: A Randomized, Open-label Phase III Study of Pemetrexed/Carboplatin/Bevacizumab Followed by Maintenance Pemetrexed/Bevacizumab Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

✍ Jyoti D. Patel; Philip Bonomi; Mark A. Socinski; Ramaswamy Govindan; Shengyan Ho 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 100 KB

O-192a SWOG 0023: A randomized phase III

O-192a SWOG 0023: A randomized phase III trial of cisplatin/etoposide(PE) plus radiation therapy followed by consolidation docetaxel then maintenance therapy with gefitinib or placebo in patients with locally advanced unresectable stage III non-small cell lung cancer (NSCLC)

✍ Kelly, K.; Gaspar, L.E.; Chanksy, K.; Albain, K.S.; Jett, J.; Ung, Y.; Crowley, 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 143 KB

Randomized phase II study of amifostine

Randomized phase II study of amifostine mucosal protection by either subcutaneous injection or rapid IV bolus for patients with inoperable stage II–IIIA/B or stage IV non-small cell lung cancer with oligometastases receiving concurrent radiochemotherapy with carboplatin and paclitaxel followed by optional consolidative chemotherapy: A follow-up study after RTOG 98-01

✍ Maria Werner-Wasik; Corey Langer; Benjamin Movsas 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 95 KB